Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.

The U.S Food and Drug Administration (FDA) granted Fast Track Designation to Sana Biotechnology’s SC291 for ...

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for ...

Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025 SEATTLE, Dec. 02 ...

Sana Biotechnology's SC291 receives FDA Fast Track designation for treating relapsed/refractory systemic lupus erythematosus, with initial data expected in 2025. Sana Biotechnology, Inc. announced ...

SEATTLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the U.S ...

The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...

Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025 SEATTLE, Dec. 02, 2024 ...

SC291 is a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T therapy. It is currently being evaluated in the company’s GLEAM trial, targeting B-cell mediated autoimmune diseases ...